Cosentyx 150 MG/ML syringeml
Ended Awarded
- Contract number
- SPE2DB25FEFXP
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $11,288
Award facts
- Contract value 100% obligated
- $11,287.68 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $11,287.68 to AmerisourceBergen Drug Corp for COSENTYX 150 mg/mL syringes under a firm fixed-price contract. The award, issued on August 6, 2025, with an ultimate completion date of August 7, 2025, represents a non-competitive, direct procurement of this specialty pharmaceutical product. COSENTYX (secukinumab) is a biologic medication used to treat autoimmune conditions including psoriasis, psoriatic arthritis, and ankylosing spondylitis, making it a critical therapeutic asset for military and veteran healthcare systems. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania.
This delivery order is issued under AmerisourceBergen's substantial Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999.99 million through December 2026, which serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs worldwide. AmerisourceBergen, a major pharmaceutical distributor headquartered in Pennsylvania, holds a significant position as a critical federal medical procurement vendor, consistently fulfilling diverse pharmaceutical and medical supply needs across multiple therapeutic domains for the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The non-set-aside designation reflects the competitive nature of the underlying IDC vehicle and AmerisourceBergen's demonstrated capability to meet federal procurement standards for specialized medical products.
Quick answers
Who was awarded contract SPE2DB25FEFXP?
SPE2DB25FEFXP was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on August 6, 2025.
How much is contract SPE2DB25FEFXP worth?
The government has obligated $11,288 on SPE2DB25FEFXP.
Is contract SPE2DB25FEFXP an order under another contract?
Yes. SPE2DB25FEFXP is a delivery order under SPE2DB24D2205, an indefinite delivery contract.
Was contract SPE2DB25FEFXP competed?
The extent of competition for SPE2DB25FEFXP was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award